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Abstract
To understand better how different genomic regions may confer pathogenicity for the
coxsackievirus B (CVB), two intratypic CVB1 variants and a number of recombinant viruses were
studied. Sequencing analysis showed 23 nucleotide changes between the parental non-pathogenic
CVB1N and the pathogenic CVB1Nm. Mutations present in CVB1Nm were more conserved than
those in CVB1N when compared to other CVB sequences. Inoculation in C3H/HeJ mice showed
that the P1 region is critical for pathogenicity in murine pancreas and heart. The molecular
determinants of disease for these organs partially overlap. Several P1 region amino acid
differences appear to be located in the decay accelerating factor (DAF) footprint CVBs. CVB1N
and CVB1Nm interacted with human CAR, but only CVB1N seemed to interact with human
DAF, as determined using soluble receptors in a plaque reduction assay. However, the murine
homologue Daf-1 did not interact with any virus assessed by haemagglutination. The results of
this study suggest that an unknown receptor interaction with the virus play an important role in the
pathogenicity of CVB1Nm. Further in vivo studies may clarify this issue.
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Introduction
Coxsackieviruses (CVs) belong to the genus Enterovirus within the Picornaviridae family
[Pallansch and Roos, 2001]. Soon after their initial isolation, CVs were divided into
subgroups A and B (CVA and CVB) according to their pathogenicity in suckling mice
[Hyypia et al., 1993]. Based on its molecular characteristics, the CVB subgroup, which
includes six serotypes, is currently classified as human enterovirus B [Fauquet et al., 2005;
Oberste, 2008]. CVs cause commonly subclinical infection, but occasionally they cause
significant disease, especially in the central nervous system (CNS) and muscle tissues, with
neonates and immunocompromised patients being particularly susceptible [Pallansch and
Roos, 2001]. CVBs cause the majority of cases of enterovirus-related viral myocarditis [Kim
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et al., 2001], a condition that has been linked to dilated cardiomyopathy [Feldman and
McNamara, 2000]. Although the role of CVB as an etiologic agent of insulin-dependent
diabetes mellitus is still controversial, this virus infects pancreatic acinar cells leading to
widespread necrosis, fulminant pancreatitis and subsequent pancreatic insufficiency
[Whitton et al., 2005]. Importantly, CVB1 was the predominant enterovirus isolated in the
USA among young infants with severe disease in 2007 [MMRW, 2008; Wikswo et al.,
2009] and continued to be the most common serotype detected in 2008 [MRRW, 2010].
Picornaviruses are small, icosahedral non-enveloped animal viruses. In many cases, their
detailed atomic structures have been determined [Filman et al., 1998; Fry et al., 2003;
Hadfield et al., 1997; Hendry et al., 1999; Hogle et al., 1985; Luo et al., 1987; Muckelbauer
et al., 1995; Rossmann et al., 1985; Verdaguer et al., 2000]. The capsid is comprised of 60
copies each of four viral proteins, VP1, VP2, VP3 and VP4, forming an icosahedral shell of
about 300 Å in diameter, which is filled with a positive-sense, single-stranded RNA
genome. The surface topology of the capsid includes a depression called the “canyon”
located near the five-fold symmetry axes. Genetic and structural studies have revealed that
the canyon is the receptor-binding site for many of these viruses [Belnap et al., 2000;
Colonno et al., 1988; Kolatkar et al., 1999; Olson et al., 1993; Rossmann et al., 2002]. When
a receptor molecule binds within the canyon, it dislodges a “pocket factor”, probably a lipid
molecule residing within a pocket immediately below the canyon surface [Rossmann, 1994].
The absence of the hydrophobic pocket factor destabilizes the virus and initiates a transition
to altered “A” particles and virion uncoating [Curry et al., 1996].
CVBs interact with at least two receptor proteins. All CVBs use the coxsackievirus-
adenovirus receptor (CAR), a 46-kDa protein that binds within the canyon [Bergelson et al.,
1997; He et al., 2001; Tomko et al., 1997]. Although an interaction with CAR is all that is
required for transition to the A-particle and subsequent uncoating [Milstone et al., 2005],
some CVBs can interact with an additional 70-kDa molecule called the decay-accelerating
factor (DAF, also known as CD-55). DAF is a complement regulatory protein that is
expressed commonly on most cell surfaces [Bergelson et al., 1995; Shafren et al., 1995].
DAF binds to the virus capsid outside the canyon [Hafenstein et al., 2007] and contributes to
the efficient infection of polarized epithelial cells [Coyne and Bergelson, 2006; Shieh and
Bergelson, 2002]. Haemagglutination seems to be associated with the use of DAF although
there are enterovirus strains with DAF affinity that do not haemagglutinate [Pasch et al.,
1999; Powell et al., 1998; Powell et al., 1999; Spiller et al., 2000].
Since CVB infection in mice resembles human infection [Cihakova et al., 2004], the murine
model has been used extensively in pathogenicity studies [Pallansch and Roos, 2001].
Important factors for determining the outcome of CVB-induced murine disease include: age,
inoculation route [Bopegamage et al., 2005], mouse strain [Cihakova et al., 2004],
nutritional status [Beck et al., 2003] and virus genotype [Chapman et al., 1997]. In addition,
it has been suggested that the 5′UTR stem loop II (SLII) structure [Dunn et al., 2000; Lee et
al., 1997] plays a major role in myocarditis [Dunn et al., 2003; Stadnick et al., 2004].
Furthermore, SLII has been found to determine virulence in CVB1-inoculated newborn mice
[Rinehart et al., 1997]. Studies have demonstrated that single mutation at VP2-165 (in the
“puff” loop) [Knowlton et al., 1996; Stadnick et al., 2004] or at VP1-155 [Cameron-Wilson
et al., 1998] are important for the myocarditic phenotype. VP1-129 and, to a lesser extent,
VP4-16 in CVB4 have been implicated as major pathogenic determinants of pancreatic
disease [Chapman et al., 1997]. Although multiple nucleotides throughout the genome have
been identified as pathogenic determinants, the pathogenic phenotype also depends on the
particular intratypic or intertypic CVB variant [Pallansch and Roos, 2001]. Nevertheless,
relatively few studies have compared molecular determinants using the same CV strain in
different organs.
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In order to identify determinants of disease and clarify the mechanism(s) involved, the
pathogenic properties of two CVB1 viruses and the intratypic recombinant viruses obtained
from them were studied. Sequence analysis showed 23 nucleotide differences between the
parental non-pathogenic CVB1N and the pathogenic CVB1Nm. The results obtained suggest
that the molecular determinants for pancreas and heart disease may differ. Mapping the
CVB1 sequence-equivalent residues to the known structure of the CVB3-DAF complex
showed that several amino acid changes in the P1 region are located within the human DAF
binding site. Although both viral variants interacted with human CAR, only CVB1N was
able to interact with human DAF. The results of this study suggest that an unknown murine
receptor interaction with the virus play an important role in the pathogenicity of CVB1Nm.
Materials and Methods
Cells
HeLa cells (American Type Culture Collection) were maintained as monolayers in minimal
essential medium (MEM), supplemented with 10% fetal calf serum, 2 mM L-glutamine,
25.5 mM sodium bicarbonate, and 50 μg/ml gentamicin. HeLa cells were used in
transfections, virus propagation, determination of growth curves and plaque assays.
Virus
An infectious CVB1 cDNA clone (CVB1N) was generously provided by Dr. A. Nomoto,
University of Tokyo, Japan [Iizuka et al., 1991]. The cDNA engineered behind the T7
promoter was in vitro transcribed after linearization with XbaI. The resultant RNA was
transfected into HeLa cells to produce infectious virus, which was purified partially by
pelleting through a 30% sucrose cushion as described previously [Rinehart et al., 1997].
To develop a pathogenic variant from this virus, a previously described protocol was used
[Hufnagel et al., 1995]. Briefly, 4-week-old severe combined immunodeficiency (SCID)
mice were intraperitoneally (i.p.) inoculated with 50 μl of Hanks’ balanced salt solution
(HBSS) containing 104 PFU of CVB1N and sacrificed at 8 weeks post-infection (p.i.). The
virus was isolated several times from heart or pancreas tissue homogenates after a single
passage in SCID mice. One heart-isolated viral strain, CVB1Nm, showed a different plaque
phenotype and was chosen for further studies. The CVB3 variant used in this study has been
described previously [Hafenstein et al., 2007]. The CVB5 (Faulkner strain) was obtained
from the Center for Disease Control (CDC), Atlanta, USA.
Cloning of a CVB1N-derived myocarditic variant and construction of chimeric cDNAs
The viral variant CVB1Nm was plaque-purified twice and semi-purified as described above.
The viral RNA was isolated and subjected to RT-PCR as described previously [Rinehart et
al., 1997]. Products obtained from nucleotides 1 to 3,448, 1,571 to 5,135 and 4,916 to polyA
were cloned into pGEM-T vector (Promega). These clones were used to construct chimeric
cDNAs between CVB1N and CVB1Nm by digestion of the parental cDNAs with restriction
enzymes that recognize unique sites. Infectious viruses were obtained from the chimeric
cDNAs as described above.
Sequence analysis
The full sequence of CVB1Nm was determined using an AmpliTaq FS dye terminator cycle
sequencing kit (Applied Biosystems) and an ABI Prism 377 DNA sequencer and was
compared to the published CVB1N sequence [Iizuka et al., 1987]. Both DNA strands of at
least two different samples were sequenced.
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To perform a comparative analysis of the mutations in the 5′UTR nucleotidic sequence,
CVB1N segments were aligned with the corresponding sequences of other human
enterovirus B (NCBI taxid:138949). Segments of 51 nts from the 5′UTR, in which each of
the mutations was centered (at position 26), were used to obtain up to 100 sequences using
BLASTn from the NCBI database. These segments were then aligned using Clustal X and
the frequency of the mutations was calculated [Altschul et al., 1997; Thompson et al., 1994].
The amino acid changes in the VPs were analyzed by a similar procedure. Segments of 21
amino acids of the encoded polyprotein, in which the mutation was centered at position 11,
were used to obtain up to 100 sequences using BLASTp and then aligned using NCBI
COBALT [Papadopoulos and Agarwala, 2007].
Plaque forming assay
The plaque assay was performed in HeLa cells as described previously [Rinehart et al.,
1997]. Briefly, confluent HeLa cells cultured in 6-well plates were incubated for 1 h (37 ºC,
5% CO2) with 20 PFU/well of each virus (three plates for each strain). After removing the
medium, infected cells were covered with 0.8% agarose and cultured for 48 h. Prior to
observation, the cells were fixed with paraformaldehyde and stained with 1% crystal violet.
One-step growth curves
A one-step growth curve with a multiplicity of infection (MOI) of 10 for each virus was
determined in HeLa cells as described previously [Rinehart et al., 1997]. The monolayer was
harvested and the virus titre was determined by plaque assay. Each time interval was
assayed in duplicate.
Animal inoculation
Weanling (3-week-old) wild-type male C3H/HeJ mice (Jackson Laboratory, Bar Harbor,
Maine) were inoculated i.p. with 50 μl of HBSS containing 104 PFU of each of the parental
or recombinant viruses. At 5 or 10 days p.i., the pancreas and heart from 5 to 10 mice were
collected from two separate experiments and processed for infectivity studies or fixed in
10% neutral buffered formalin, respectively, as described previously [Gomez et al., 1996].
All animal procedures were approved by the UNLP Animal Care and Use Committee.
Histopathology studies
Samples were embedded in paraffin, oriented along their longest axis and at least three 5-
μm sections were stained with haematoxylin and eosin for histopathological examination.
Pancreatitis and myocarditis were graded blindly by two pathologists on a scale of 0 to 4
using a whole longitudinal section of the organ: a score of 0 corresponded to the absence of
cellular infiltration or necrosis, 1 to minimal inflammation (1 to 5 foci), 2 to mild
inflammation (less than 25% of the pancreas section affected or 6 to 10 foci in the heart), 3
to moderate inflammation (25 to 50% of the pancreas section affected or 11 to 20 foci in the
heart) and 4 to severe inflammation (more than 50% of the pancreas tissue section showed
infiltration or necrosis or more than 20 foci in the heart).
Mutation mapping
The site of each mutation was established using equivalent CVB1 residues based on
sequence alignment with the known structure of the closely related CVB3 [Muckelbauer et
al., 1995]. Receptor footprints were obtained from cryo-electron microscopy (cryo-EM) of
the reconstruction structures of CVB3 interacting with CAR [He et al., 2001] and of CVB3
(RD strain) interacting with the cellular co-receptor DAF [Hafenstein et al., 2007].
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Human DAF was expressed in Pichia pastoris as a C-terminally 6xHis-tagged protein, as
described previously [He et al., 2002]. The DAF construct consisted of the full-length
ectodomain containing SCR-1, -2, -3, and -4 (amino acids 1 to 254) but lacking the S/T-rich
linker domain and the glycosylphosphatidylinositol anchor. The CAR ectodomain protein
(D1D2) used in the plaque reduction assays was provided by Paul Freimuth (Brookhaven
National Laboratory) and produced and purified as described previously [He et al., 2001].
Haemagglutination studies
Human (Type 0 Rh-) and murine (BALB/c mice) erythrocytes were collected in 15 mM
EDTA (final concentration) and washed three times with 50 volumes of PBS. A 0.5%
suspension of washed erythrocytes was made in PBS. Viral dilutions were performed by
adding 1 ml of sucrose-gradient purified CVB serotypes to 100 ml of PBS. Equal volumes
of serially diluted virus and erythrocytes were mixed in V-bottom 96-well plates (Costar
Bio-Rad, USA) and incubated at 4 °C for 4 h. CVB1N, CVB1Nm and CVB5 (positive
control) were tested.
Statistics
Data were expressed as the mean ± S.E.M. and were analysed by one-way analysis of
variance (ANOVA) followed by a Bonferroni multiple comparison test to determine




To obtain viral variants, CVB1N was inoculated into SCID mice and viral isolations were
obtained from various tissues. One of the heart tissue isolations presented a different plaque
phenotype (Figure 1) and was chosen for further studies. This variant, CVB1Nm, was
cloned and sequenced completely. Sequencing analysis showed 23 nucleotide changes from
the parental strain CVB1N (Table I). Many of these mutations mapped to regions previously
reported to affect pathogenicity, including two mutations in SLII, eight amino acid changes
and one amino acid insertion in the P1 region, and three amino acid changes in the viral
polymerase 3D.
Each mutation, was placed in the center of a selected protein (or RNA) segment and used as
query sequence against the human enterovirus B data base (taxid:138949) (see methods).
The resulting sequences were then aligned and analyzed. The frequency of occurrence was
determined according to the identity of the residue of interest, based on whether the identity
was that found in CVB1N, CVB1Nm or other virus.
The analysis of nucleotide identity at the positions of interest in the 5′UTR showed that, in
general, the nucleotides corresponding to CVB1Nm were found more frequently than those
corresponding to the parental CVB1N. In particular at nt 35 in the loop I “cloverleaf”, the
CVB1Nm nucleotide was found with a frequency of 89% versus 11% for the deletion found
in CVB1N. At nts 118 and 133, both located in the stem loop II, the frequency was 49% and
61%, respectively for CVB1Nm whereas the frequency was 4% and 9%, respectively for
CVB1N. Located between loops III and IV at nt 606, the frequency of the mutant nucleotide
was 74%. However, at nt 118, both the G corresponding to CVB1Nm and the gap for
CVB1N were found with similar frequencies. Finally, the deletion of C at nt 184 in the
mutant, was not found in the database (Figure 2A).
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A similar analysis was performed to compare the amino acid sequence of the P1 region with
other human enterovirus B. The results for VP1 showed that for position 80, 107 and 125,
those residues in CVB1Nm were common, with frequencies greater than 33%. However, the
same position for the residue in the parental strain was found in less than 7% of the
sequences. At position 274 both residues were found at similar frequencies. In contrast, at
position 155 the residue found in CVB1N was frequent but that of CVB1Nm was rare. In
VP3 the frequency of the mutant residue at position 80 (10%) was higher than that of the
parental residue (5%). The CVB1Nm identity of the residue at VP3-79 is highly conserved
(85%). Mutation at VP3-60 and VP2-165 showed low frequencies for both the parental and
the mutant. On the other hand, the residue at VP4-60 is highly conserved and matched that
found in CVB1N; the mutant residue was not found (Figure 2B). Taken together, these
results indicate that mutations present in CVB1Nm are closer to the consensus sequence
than CVB1N, from a comparison with other human enterovirus B sequences.
Growth capabilities of recombinant viruses on HeLa cells
To identify determinants of disease and to clarify the mechanism(s) involved, several
intratypic recombinant viruses were obtained. The restriction enzymes used and mutations
included in each recombinant virus are shown in Figure 1.
The growth capabilities of recombinant and parental viruses were studied in HeLa cells.
Enhanced replication was observed in the CVB1Nm, C69-805, C69-4318 and C69-1847
intratypic recombinant viruses (Figure 3). In contrast, the kinetics of the C932-2288
recombinant virus was similar to that of the parental virus CVB1N (Figure 3). These results
suggest that the 5′UTR of CVB1Nm is responsible for the enhanced replication observed in
cell culture.
Pathogenic properties in mice
To characterize the phenotype of CVB1N, CVB1Nm and the intratypic recombinant viruses
in vivo, viruses were inoculated separately into C3H/HeJ weanling mice. Histological
examination of samples from the CVB1N-infected mice (Figure 4A–B) showed no
difference from mock-infected mice (Figure 4M–N). In contrast, CVB1Nm induced severe
pancreatitis and myocarditis (Figure 4C–D) with moderate mortality (<20%). CVB1Nm
viral titres in the pancreas and heart were 7.5±0.8 and 6.6±06, respectively (Figure 2).
Recombinant viruses C69-6365 and C69-4318 (Figure 4E–F) displayed the same pathogenic
phenotype as CVB1Nm. Pancreatic and cardiac viral titres for C69-6365 and C69-4318
(7.2±0.4 and 6.4±0.4, respectively for the former recombinant virus; 7.1±0.7 and 6.2±0.6,
respectively for the latter recombinant virus) were similar to those obtained for CVB1Nm
(Figure 1). However, recombinant virus C3438-6365 was not pathogenic (data not shown)
and the viral titres in both organs analysed were below the assay detection limit (Figure 1),
suggesting that the genomic region comprising nucleotides 69 to 3438 is important for the
pathogenic properties observed after CVB1Nm inoculation. Recombinant virus C69-805
induced a small number of lesions in the pancreas and heart (Figure 4G–H), indicating that
the 5′UTR is not critical for pathogenicity in the CVB1Nm variant. Recombinant viruses
C69-1847 (Figure 4I–J) and C932-2288 induced only a few small, scattered necrotic foci in
the myocardium (Figure 4L) but induced more severe pathological changes in the pancreas
(Figure 4K). Viral titres correlated with the histopathology results. The data are summarized
in Figure 1. These results suggest that major determinants for CVB1Nm pathogenicity are
located in the P1 region and that mutations in the 5′UTR and 3C do not contribute to
disease. Furthermore, mutations in VP1 are necessary for myocarditis and contribute to
pancreatitis. In contrast, mutations located in VP2, 3 and 4 directly contribute to pancreatitis
but do not induce myocarditis.
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The amino acid sequences of the P1 regions of CVB3 and CVB1Nm share more than 80%
similarity and probably have similar secondary structures and characteristics, including
receptor usage. The known structure of CVB3 (pdb code 1COV) was used to approximate
the location of the sequence-equivalent residues corresponding to the nine mutations in the
CVB1Nm P1 region. Mutation VP4-60 is located at the internal surface of the capsid near
the three-fold symmetry axes, whereas mutation VP1-107, an L insertion, is buried within
the capsid protein shell, located about 10Å beneath the canyon adjacent to the pocket. All of
the remaining seven mutations map to the external surface of the virus capsid. Mutations at
VP2-165, VP3-60 and VP1-274 are located within the DAF footprint. Mutations at VP1-155
and VP3-79 are adjacent to viral residues known to interact with DAF (Figure 5A) [He et
al., 2002]. In contrast, none of the mutations present in the P1 region of CVB1Nm are
located within the CAR binding site or predicted to interact with CAR, as suggested by the
3-D structure (Figure 5B). Residue VP2-165 has been reported to be a possible contact
residue with CAR, based on its distance from the fitted CAR structure bound within the viral
‘canyon’ [He et al., 2001]. However, CVB1Nm VP2-165 maps to a location on the opposite
side of the puff, with the top of the puff sterically blocking the direct access of VP2-165 to
the canyon (Figure 5B).
Receptor binding properties
Capsid surface topology dictates receptor recognition and makes a major contribution to the
tropism of the virus. Since the P1 structural region is likely to be responsible for the
pathogenic phenotype and seven of the mutations map to the capsid surface, receptor usage
was investigated. One of the mutations was within the known CAR binding footprint of
CVB3 and four of the mutations detected in CVB1Nm mapped within or adjacent to the
DAF footprint. Therefore, plaque reduction assays using CVB1N, CVB1Nm, CVB3
(positive control) alone or pre-incubated with either soluble hCAR or DAF were performed
to characterize receptor usage [Hafenstein et al., 2007]. More than 2-log reductions in
plaque number were observed when each virus was pre-incubated with soluble hCAR
compared to virus alone (Table II, P<0.05). In contrast, an approximately 1-log reduction
was observed when CVB1N, but not CVB1Nm, was pre-incubated with soluble DAF (Table
II, P<0.05). These results suggest that the attenuated parental CVB1N may have an affinity
for DAF that has been lost by the pathogenic CVB1Nm.
It has been reported that CVBs that bind the human DAF receptor do not bind murine DAF
[Spiller et al., 2000]. In addition, although some CVBs with affinity for DAF do not
haemagglutinate, haemagglutination has been associated with the use of DAF [Powell et al.,
1998; Powell et al., 1999; Spiller et al., 2000]. Since the CVB1Nm mutant was developed in
SCID mice, haemagglutination assays with human or murine erythrocytes incubated with
purified CVB1N or CVB1Nm were performed in order to explore whether the mutations
have a role in haemagglutination and thus, DAF affinity. The CVB5 Faulkner strain with
known haemagglutination properties was employed as a positive control. Both CVB1N and
CVB5 agglutinated human erythrocytes, but CVB1Nm failed to show any
haemagglutination activity. As expected, none of the viruses agglutinated murine
erythrocytes (Table III).
Discussion
A few genomic differences can lead to significant changes in the phenotype of RNA viruses
[Domingo et al., 2006]. The CVB1Nm sequence revealed 23 nt changes compared to the
CVB1N sequence, five of which were silent changes. Of special interest were those
mutations located in the 5′UTR, particularly in and downstream of the SLII region, as this
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region has been associated with CVB3 pathogenic determinants of myocarditis [Chapman et
al., 1997] and CVB1 virulence [Rinehart et al., 1997; Zhong et al., 2008]. Since nucleotide
changes in CVB1Nm allowed for a more conserved sequence than CVB1N with respect to
other CVB sequences, these mutations could underlie the non-attenuated phenotype of
CVB1Nm. In addition, the studies performed on HeLa cells with the parental and
recombinant viruses demonstrated that the presence of the 5′UTR of CVB1Nm led to
enhanced replication. Two cellular RNA-binding proteins are known to interact with the
SLII of VP1: the translation factor eIF-2α interacts with nucleotide regions 97 to 182 and
510 to 629 [del Angel et al., 1989], whereas the polypyrimidine tract-binding protein
interacts with nucleotide regions 70 to 288, 443 to 539 and 630 to 730 [Hellen et al., 1994].
Mutations in the 5′UTR of CVB1Nm may influence viral replication efficiency in a cell
type-specific fashion by affecting viral RNA translation and/or synthesis, a major
determinant of virulence [Sonenberg and Dever, 2003].
Although several studies have characterized the molecular determinants of disease following
infection with intratypic or intertypic CVB variants, relatively few have compared the
molecular determinants of disease in the main target organs using the same virus. The
pancreas and heart pathogenicity studies showed that although several chimeric viruses were
pathogenic for the pancreas, only a few induced myocarditis and none of them induced
myocarditis in the absence of pancreatitis. In addition, those viruses that achieved high titres
in the pancreas were also virulent in the heart, whereas those that achieved intermediate
titres in the pancreas induced an intermediate level of pancreatitis and virtually no
myocarditis. Based on the chimeric studies, the determinants that are related to
cardiovirulence also include those related to producing high viral titres in the pancreas.
Furthermore, it is likely that more than one determinant accounts for cardiopathogenicity,
because one change led to dramatic attenuation in myocarditis without an attendant
reduction in pancreatitis. However, the opposite was not observed, as a reduction in
pancreatitis was always concomitant with a reduction in myocarditis, as in previous studies
[Kallewaard et al., 2009; Tracy et al., 2000].
Characterization of the chimeric viruses showed that the molecular determinants of
pancreatitis and myocarditis in CVB1Nm-infected C3H/HeJ mice were also located in the
P1 region. Although the P1 region had been implicated previously by a comparison of
CVA9 and CVB3 [Harvala et al., 2005; Harvala et al., 2002], this is the first study to
conclude that the P1 region contains determinants of pathogenicity using a single parental
virus CVB1 and its variant isolated from a single passage in mice.
A number of antibody escape mutants of CVB3 that cause cardiac and pancreatic disease
have been characterized previously [Stadnick et al., 2004], in which (i) a VP2-158 K to R
mutation and a VP3-60 E to G lead to attenuation of the virus with respect to myocarditis
but with only a partial reduction in pancreatitis; (ii) the presence of two mutations in the
5′UTR (a C-to-U transition at nucleotide 119 in SLII and a C-to-U transition at nucleotide
609) that were associated with enhanced pancreatic and cardiac disease. These authors also
suggested that the escape mutants’ P1 mutations affected the virus–DAF interaction based
on data extrapolated from the EV7–DAF interaction. A number of pathogenic CVB3
antibody escape mutants became attenuated in a murine model [Stadnick et al., 2004]. In
contrast, the present study used a non-pathogenic variant of CVB1 that became pathogenic
after a single passage in SCID mice. Given these different approaches, it is interesting that
both studies found that mutations in similar genomic areas had a greater effect on
myocarditis than pancreatitis in the murine model. This similarity suggests the existence of
‘hot spots’ along the genome that influence the pathogenic phenotype of CVs, whether the
virus is an antibody escape mutant generated in vitro or a murine-adapted virus. Comparison
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of genomic sequences obtained from the data bank showed that this could also apply to
human-isolated viruses.
The mapping of the equivalent CVB1 residues was based on the known structure of CVB3.
However there may be slight differences in the topography of the actual CVB1 puff
structure that may affect the predicted interactions between receptor residues and CVB1Nm
VP2-165. Most of the CVB1Nm mutations mapped to the DAF-binding site, instead of the
CAR binding site. Although all CVB viruses require CAR to initiate a productive infection,
affinity for the DAF co-receptor appears to be more variable [Shieh and Bergelson, 2002].
On the other hand, it has been reported previously that CVBs that use human DAF as a
receptor do not bind murine DAF [Spiller et al., 2000]. In this regard, the results obtained
here showed that although CVB1N agglutinated human erythrocytes, neither CVB1N nor
CVB1Nm haemagglutinated murine red blood cells. Furthermore, soluble hCAR
significantly reduced the number of plaques induced by both viruses, whereas soluble DAF
reduced only the number of CVB1N plaques and to a lower extent. These results suggest
that both CVB1N and CVB1Nm variants use CAR, but that only CVB1N may use DAF.
However, since some CVBs that do not haemagglutinate have DAF affinity, these data
should be interpreted with caution. Furthermore, mutations in CVB1N may result in a viral
variant that interacts differently with murine CAR, although the possibility of an interaction
with another unidentified receptor cannot be excluded and has also been suggested by others
[Orthopoulos et al., 2004].
The L insertion at VP1-107 of CVB1Nm is not directly related to the CAR or DAF footprint
as it is located between the α-helix A and β-strand D, adjacent to the pocket beneath the
canyon [Muckelbauer et al., 1995]. It has been suggested that the drug-binding cavity itself
and not the putative pocket factor is crucial for capsid dynamics and infection of
rhinoviruses [Katpally and Smith, 2007]. Consequently, this amino acid insertion may alter
the local structure, affecting the capsid dynamics.
In summary, the major determinants of CVB1’s pathogenicity in the murine model are
located in the P1 region and may differ according to the organ. Furthermore, critical residues
on the viral surface map to the known DAF binding site, although the murine homologue
Daf-1 does not seem to interact with any virus. The results obtained here suggest that an
unknown murine receptor interaction with the virus plays an important role in the
pathogenicity of CVB1Nm. Further studies may clarify this issue.
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Figure 1. Schematic representation of CVB1 parental and recombinant viruses, viral titres and
pathology score
The restriction sites used to obtain the constructs are noted above the margins of the
chimeric segments. CVB1N segments are shown as open bars while CVB1Nm segments are
shown as solid bars. The pathology score was obtained as described in the text. Viral titres
are expressed as log10 TCID50±SE per gram of tissue; <2 indicates that the infectivity was
below the limit of the sensitivity assay. All determinations were performed using tissues
corresponding to the C3H/HeJ mice shown in Figure 4.
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Figure 2. Sequencing studies
A: Bar chart showing frequency of identical nucleotides (including gaps) of the 5′UTR (A)
and identical amino acid residues for the capsid proteins (B) from alignments with other
human enterovirus B (taxid:138949). The frequency of matching identity is shown for
CVB1Nm (black), CVB1N (white), with unmatched identity indicated in grey.
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Figure 3. Comparative studies on HeLa cells
One-step growth curves with a multiplicity of infection (MOI) of 10 for each virus were
performed on HeLa cells. At the indicated time points after infection, cells were washed
with 0.1 ml of PBS, harvested and freeze-thawed three times. The live viral particles were
counted using a plaque-forming assay. P<0.05 after comparison of CVB1N and C932-2288
with CVB1Nm and the remaining recombinant viruses. p.i.= post-inoculation.
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Figure 4. Representative histology of murine pancreas and heart after inoculation with CVB1N,
CVB1Nm and intratypic recombinant viruses
Ten days after inoculation of weanling male C3H/HeJ with these viruses, the pancreas and
heart were harvested and processed for routine staining with haematoxylin and eosin.
Representative sections from the pancreas (right panels) and myocardium (left panels) of
mice inoculated with CVB1N (A–B), CVB1Nm (C–D), C69-4318 (E–F), C69-805 (G–H),
C69-1847 (IJ), and C932-2288 (K–L) are shown. Scale bars: 125 μm.
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A: The viral surface is represented as a quilt of amino acids and shown as a stereographic
projection, where the polar angles θ and ϕ represent latitude and longitude, respectively
[Xiao and Rossmann, 2006]. The viral icosahedral asymmetric unit is indicated by the
triangular boundary. The DAF footprint for echoviruses (a grey outline) was plotted using
the equivalent CVB3 residues based on multiple sequence alignments [Chenna et al., 2003]
according to the DAF contact residues for EV7 [He et al., 2002] and EV12 [Bhella et al.,
2004]. EV and CVB3 have a sequence identity of 61% for VP1, 70% for VP2 and 67% for
VP3. The DAF footprint on CVB3 is outlined in black. Mutations are indicated in black.
VP1-155 and VP3-79 are highlighted in neighbouring asymmetric units. Five of the seven
amino acid changes, which map to the viral surface, are located within areas of CVB3 that
are known to interact with DAF. ‘ Denotes symmetry-related amino acids. B: This figure
was obtained using Chimera [Pettersen et al., 2004; Sanner et al., 1996]. One protomer of
the CVB3 surface rendered with a symmetry-related copy of VP3 to show the canyon and
CAR binding region, relative to the location of the CVB1Nm surface residue changes. None
of the mutations are within the CAR binding site. The closest residue, VP2-165, is located
opposite the puff at a distance from the canyon.
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Table II
CVB1 interaction with soluble human CAR and DAF evaluated by reduction plaque assays.
Virus +hCAR +hDAF
CVB1N 2 log reductions* 1 log reductions*
CVB1Nm 2 log reductions* 0 log reductions
CVB3 2 log reductions* 0 log reductions
*
P<0.05; hCAR (human coxsackievirus-adenovirus receptor); hDAF (human decay-accelerating factor).
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Table III








hRBC (human red blood cells); mRBC (murine red blood cells).
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